Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for managing type 2 diabetes and chronic weight management [1]. It is administered as a daily injection and works by stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and increasing satiety [1][2].
When does liraglutide's patent protection expire?
The primary patents protecting liraglutide, specifically for Novo Nordisk, have largely expired or are nearing expiration in major markets. For example, key patents for the original formulations of liraglutide expired around 2023 [3]. DrugPatentWatch.com provides detailed patent expiry information for liraglutide [3].
What are the different forms of liraglutide available?
Liraglutide is available under different brand names depending on its indication. Victoza is prescribed for type 2 diabetes, while Saxenda is approved for chronic weight management [1][2]. These formulations contain the same active ingredient, liraglutide, but are dosed and indicated differently [1].
Can generic or biosimilar versions of liraglutide be manufactured?
With the expiry of primary patents, the pathway for generic or biosimilar versions of liraglutide opens up. The development and approval of biosimilars are complex processes that require demonstrating similarity in terms of safety, efficacy, and quality to the reference product [4]. Companies are actively developing and seeking approval for biosimilar versions of liraglutide [5].
How does liraglutide work in the body?
Liraglutide mimics the action of the natural human hormone GLP-1. In the pancreas, it enhances glucose-dependent insulin secretion and reduces glucagon secretion. It also slows down the rate at which food leaves the stomach, which contributes to a feeling of fullness, and acts on the brain to reduce appetite [1][2].
What are the risks and side effects associated with liraglutide?
Common side effects of liraglutide include nausea, vomiting, diarrhea, constipation, and abdominal pain [1]. More serious, though less common, side effects can include pancreatitis, gallbladder problems, and thyroid tumors [1][6]. There is also a boxed warning regarding the potential risk of thyroid C-cell tumors in rats, although the relevance to humans is not fully understood [1][6].
How does liraglutide compare to other diabetes or weight loss medications?
As a GLP-1 receptor agonist, liraglutide belongs to a class of drugs that have shown significant efficacy in glycemic control and weight reduction. It is often compared to other GLP-1 receptor agonists like semaglutide and dulaglutide, as well as other classes of diabetes medications like SGLT2 inhibitors and DPP-4 inhibitors, and weight loss medications like phentermine-topiramate and naltrexone-bupropion [7][8]. Differences lie in their efficacy, dosing frequency, side effect profiles, and cardiovascular outcome data [7][8].
What is the cost of liraglutide and its potential generics?
The cost of liraglutide (Victoza and Saxenda) can be significant, with prices varying based on dosage, insurance coverage, and geographic location [9]. The introduction of generic or biosimilar versions is expected to lead to lower prices over time, making the treatment more accessible [5].
Sources:
[1] https://www.rxlist.com/liraglutide-oral-drug.htm
[2] https://www.webmd.com/drugs/2/drug-152394/liraglutide-injection/details
[3] https://drugpatentwatch.com/drugs/liraglutide
[4] https://www.fda.gov/news-events/fact-sheets/biosimilars-and-interchangeable-biosimilars-patients-and-consumers
[5] https://www.fiercepharma.com/pharma/will-novo-nordisk-lose-bag-next-generation-weight-loss-drug-semaglutide-patents-could-face-challenges
[6] https://www.medicines.org.uk/emc/product/5430/smpc
[7] https://www.nejm.org/doi/full/10.1056/NEJMoa1611747
[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407350/
[9] https://www.goodrx.com/liraglutide